Varigenix™ Hepatocyte Panels for Early Toxicity Testing
June 22, 2011 - Unanticipated drug-induced toxicity is a major obstacle for drug development programs. Adverse reactions can halt development plans and end clinical trials. These reactions are often the result of individual patient genetic variation. Evaluating the effects of genetic variation on drug metabolism has become a critical aspect of early drug screening and an overall way to improve clinical success.
Overview of Varigenix™ Hepatocyte Panels
The Varigenix™ hepatocyte panels are a new tool set for studying the possible biologic effects of genetic variation. Characterized for genotypes and metabolic activity (ECOD), these panels express genetic variability comparable to human populations. They are comprised of cryopreserved BXD mouse hepatocytes with ≥80% post-thaw viability at one million cells/vial.
Application of Varigenix™ Hepatocyte Panels
The Varigenix™ hepatocyte panels make it possible to predict, prior to the start of clinical trials, the potential of human subpopulations to show drug toxicity. Among many biomedical uses, they allow for the evaluation of variation in drug metabolism, drug effectiveness, drug toxicity and environmental toxin interactions.
Four Panels to Choose From
(Note: only Panel 1 is available – others will be available based on market demand)
Varigenix™ hepatocyte panels are derived from the BXD family of mouse strains, which is the largest set of recombinant inbred mouse strains used for genetic analysis (as well as the most completely phenotyped). All of these strains are available for in vivo analysis and validation (and gene expression data can be openly accessed at www.genenetwork.org).
The genomes of the BXD strains used in Varigenix™ hepatocyte panels are genotyped at thousands of SNP markers and microsatellites. This makes it possible to map the potential genetic basis of drug and toxin responses and liver toxicity.
Discover the value of the Varigenix™ hepatocyte panels and their potential utility as a part of your drug development program by clicking here. For more information, please contact Rob Kaiser at firstname.lastname@example.org or +919.462.8338.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.
We offer a package of well-established, state of the art in vitro mode of action assays that are suitable for early phase biocomparability studies, lot release and stability. These tests can accelerate the time it takes to get a new product ready for market submission.
May 28–Jun 01
The International Bone and Mineral Society (IBMS) and the Japanese Society for Bone and Mineral Research (JSBMR) are excited to sponsor the second joint scientific meeting by the two organizations.
May 23–May 23
This full-day seminar encompasses selected topics from our Charles River Short Course on Laboratory Animal Science. We would like to acknowledge Michigan State University for hosting this event and extend our heartfelt thanks to guest speaker Dr. Danielle Ferguson.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.